Treatment of vascular graft infections: gentamicin-coated ePTFE grafts reveals strong antibacterial properties in vitro

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Igor Lazic - , Technical University of Munich (Author)
  • Andreas Obermeier - , Technical University of Munich (Author)
  • Bettina Dietmair - , Technical University of Munich (Author)
  • Wolfgang E Kempf - , Technical University of Munich (Author)
  • Albert Busch - , Klinikum Rechts der Isar (MRI TUM), Technical University of Munich (Author)
  • Jutta Tübel - , Technical University of Munich (Author)
  • Jochen Schneider - , Technical University of Munich (Author)
  • Rüdiger von Eisenhart-Rothe - , Technical University of Munich (Author)
  • Peter Biberthaler - , Vanderbilt School of Medicine (Author)
  • Rainer Burgkart - , Technical University of Munich (Author)
  • Dominik Pförringer - , Vanderbilt School of Medicine (Author)

Abstract

Vascular graft infections (VGI) are severe complications in prosthetic vascular surgery with an incidence ranging from 1 to 6%. In these cases, synthetic grafts are commonly used in combination with antimicrobial agents. Expanded polytetrafluoroethylene (ePTFE) is in clinical use as a synthetic graft material and shows promising results by influencing bacterial adhesion. However, the literature on antibiotic-bound ePTFE grafts is scarce. Gentamicin is a frequently used antibiotic for local treatment of surgical site infections, but has not been evaluated as antimicrobial agent on ePTFE grafts. In this study, we examine the antimicrobial efficacy and biocompatibility of novel types of gentamicin-coated ePTFE grafts in vitro. ePTFE grafts coated with gentamicin salt formulations with covalently-bound palmitate were evaluated in two drug concentrations (GP1.75% and GP3.5%). To investigate effects from types of formulations, also suspensions of gentamicin in palmitate as well as polylactide were used at comparable levels (GS + PA and GS + R203). Antibacterial efficacies were estimated by employing a zone of inhibition, growth inhibition and bacterial adhesion assay against Staphylococcus aureus (SA). Cytotoxicity was determined with murine fibroblasts according to the ISO standard 10993-5. Gentamicin-coated ePTFE grafts show low bacterial adherence and strong antibacterial properties in vitro against SA. Bactericidal inhibition lasted until day 11. Highest biocompatibility was achieved using gentamicin palmitate GP1.75% coated ePTFE grafts. ePTFE grafts with gentamicin-coating are effective in vitro against SA growth and adherence. Most promising results regarding antimicrobial properties and biocompatibility were shown with chemically bounded gentamicin palmitate GP1.75% coatings. Graphical abstract.

Details

Original languageEnglish
Article number30
JournalJournal of materials science. Materials in medicine
Volume33
Issue number3
Publication statusPublished - 10 Mar 2022
Peer-reviewedYes
Externally publishedYes

External IDs

PubMedCentral PMC8913444
Scopus 85126168661

Keywords

Keywords

  • Animals, Anti-Bacterial Agents/pharmacology, Blood Vessel Prosthesis, Coated Materials, Biocompatible/pharmacology, Gentamicins/pharmacology, Mice, Polytetrafluoroethylene